tradingkey.logo
tradingkey.logo
Search

Sagimet Biosciences Inc

SGMT
Add to Watchlist
7.610USD
+0.150+2.01%
Close 07/02, 13:00ETQuotes delayed by 15 min
247.97MMarket Cap
LossP/E TTM

TradingKey Stock Score of Sagimet Biosciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

Sagimet Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 92 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.36.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sagimet Biosciences Inc's Score

Industry at a Glance

Industry Ranking
92 / 387
Overall Ranking
202 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Sagimet Biosciences Inc Highlights

StrengthsRisks
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -5.68, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.88M shares, decreasing 24.92% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 135.74K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.34.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
26.364
Target Price
+253.40%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Sagimet Biosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Sagimet Biosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Sagimet Biosciences Inc’s performance and outlook.

How do we generate the financial health score of Sagimet Biosciences Inc?

To generate the financial health score of Sagimet Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Sagimet Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Sagimet Biosciences Inc.

How do we generate the company valuation score of Sagimet Biosciences Inc?

To generate the company valuation score of Sagimet Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Sagimet Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Sagimet Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Sagimet Biosciences Inc.

How do we generate the earnings forecast score of Sagimet Biosciences Inc?

To calculate the earnings forecast score of Sagimet Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Sagimet Biosciences Inc’s future.

How do we generate the price momentum score of Sagimet Biosciences Inc?

When generating the price momentum score for Sagimet Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Sagimet Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Sagimet Biosciences Inc.

How do we generate the institutional confidence score of Sagimet Biosciences Inc?

To generate the institutional confidence score of Sagimet Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Sagimet Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Sagimet Biosciences Inc.

How do we generate the risk management score of Sagimet Biosciences Inc?

To assess the risk management score of Sagimet Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Sagimet Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Sagimet Biosciences Inc.